Answers are grounded in this paper and cite their sources.
Hepatocellular carcinoma (HCC) is characterized by high incidence and mortality rates, posing a severe challenge to global public health. CD-2e, a novel curcumol derivative, has demonstrated promising antitumor activity; however, its therapeutic development is hindered by poor aqueous solubility, limited circulation stability, weak cellular uptake, and low tumor accumulation efficiency. To overcome these limitations, we developed a CD-2e-loaded glycyrrhetinic acid (GA)-modified manganese-doped mesoporous silica nanoparticle system (GA-Mn-MSNs@CD-2e) for targeted and tumor microenvironment-responsive drug delivery. Mesoporous silica nanoparticles (MSNs) enhanced the loading capacity for CD-2e and helped improve its aqueous dispersibility, while GA modification promoted specific uptake by HCC cells through active targeting. After internalization, the tumor microenvironment triggered the cleavage of Mn-O bonds, enabling controlled release of CD-2e. Both in vitro and in vivo studies demonstrated that GA-Mn-MSNs@CD-2e significantly enhanced cellular uptake, prolonged tumor retention, and improved antitumor efficacy. In addition, GA-Mn-MSNs@CD-2e showed potential in modulating macrophage polarization and remodeling the tumor microenvironment. Overall, this intelligent nanodelivery system effectively addresses the major delivery barriers associated with CD-2e and provides a highly promising strategy for precise and efficient HCC therapy.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: